Literature DB >> 7918074

Gene amplification in non-Hodgkin's lymphoma.

D Ben-Yehuda1, J Houldsworth, N Z Parsa, R S Chaganti.   

Abstract

Among 426 consecutively ascertained and karyotypically abnormal non-Hodgkin's lymphoma (NHL) tumours, cytological evidence for gene amplification in the form of homogeneously staining regions (HSRs) was encountered in nine cases of large cell diffuse lymphoma (LC-DL). The mean age of patients with HSRs was 62.9 years and four died within a year of diagnosis. To identify candidate gene(s) amplified in these tumours, we performed a Southern blot analysis of tumour DNA using probes for 23 known protooncogenes and the multidrug resistance gene, PGY1. Besides a two-fold amplification of the BCL2 gene in two cases, no evidence for overt amplification of any of the genes assayed was found. To confirm DNA amplification in these specimens we performed the DNA in-gel renaturation assay. Evidence for presence of amplified DNA fragments was obtained in four of seven specimens. These results suggest amplification of a novel gene(s). To our knowledge, this is the first formal study of gene amplification in a large consecutively ascertained series of fresh lymphoma biopsies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7918074     DOI: 10.1111/j.1365-2141.1994.tb04831.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  High-level DNA amplifications are common genetic aberrations in B-cell neoplasms.

Authors:  C A Werner; H Döhner; S Joos; L H Trümper; M Baudis; T F Barth; G Ott; P Möller; P Lichter; M Bentz
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics.

Authors:  J M Hernández; J L García; N C Gutiérrez; M Mollejo; J A Martínez-Climent; T Flores; M B González; M A Piris; J F San Miguel
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

Review 3.  Primary central nervous system lymphomas--new pathological developments.

Authors:  K A Jellinger; W Paulus
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.